Adapthealth Corp., of Plymouth Meeting, Pa., entered definitive agreements to acquire San Diego-based Solara Medical Supplies LLC and Minneapolis-based Activstyle Inc. Adapthealth intends to fund the transactions and associated costs through a combination of incremental debt and newly issued equity. It committed financing from its core lender group for an incremental $240 million add-on to its existing term loan A facility. It also received commitments for equity investments of $190 million from One Equity Partners (in the form of common stock and nonvoting stock) and $35 million from funds managed by Deerfield Management (in the form of nonvoting stock), and is issuing $62.5 million in common stock to the sellers of Solara, including Linden Capital Partners, as part of the consideration for Solara. The company expects to fund any remaining amounts from cash on hand or through its current line of credit.

Archerdx Inc., of Boulder, Colo., reported a strategic collaboration with Astrazeneca plc, of Cambridge, U.K., to develop assays to support multiple planned phase III clinical trials for the latter's targeted immuno-oncology therapeutics. Archerdx will perform whole exome sequencing of resected non-small-cell lung cancer patient samples and generate patient-specific circulating tumor DNA assays. Archerdx plans to leverage the assays to develop companion diagnostics for Astrazeneca's associated therapies. The companies ultimately plan to seek global regulatory approval if the phase III clinical trials are completed successfully. The assays are currently for investigational use only. The master collaboration agreement also allows for expansion into additional disease indications and therapeutic categories.

Cerus Corp., of Concord, Calif., submitted a premarket approval supplement to the U.S. FDA for a pathogen reduced cryoprecipitated fibrinogen complex with five-day post thaw storage. It previously was granted FDA breakthrough device designation based on the potential to improve treatment of massive hemorrhage.

Echelon Diagnostics Inc., of Reno Nev., reported the commercial launch of the Safekey Health Passport. Safekey is a new mobile enterprise application for the secure collection, storage and retrieval of employee COVID-19 diagnostic and immunity testing, as well as vaccination status.

Singapore med-tech company Histoindex Pte. Ltd. said that in the latest edition of China's Guidelines for the Prevention and Treatment of Chronic Hepatitis, its artificial intelligence-based stain-free digital pathology was recommended for use in providing an automated and quantitative analysis of the liver's morphological characteristics in unstained liver biopsies with high repeatability and accuracy.

Leica Biosystems GmbH, of Nussloch, Germany, and Minneapolis-based Bio-Techne Corp. reported the European launch of Bio-Techne’s CE-IVD-marked RNAscope In Situ Hybridization Detection Kit for automation on Leica’s Bond III platform.

Paris-based Mauna Kea Technologies SA said the Society of American Gastrointestinal and Endoscopic Surgeons Technology and Value Assessment Committee has endorsed confocal laser endomicroscopy as a safe and effective tool for diagnosing gastrointestinal pathologies. Mauna Kea’s flagship product is the Cellvizio endomicroscopy system.

The Multi-Scale Robotics Lab at Eidgenössische Technische Hochschule Zürich and Ninety One Inc., of New York, have partnered to advance precision medicine and surgical robotics through advanced artificial intelligence and machine learning. 

Repro Med Systems Inc., dba Chester, N.Y.-based Koru Medical Systems, and Emed Technologies Corp., of El Dorado Hills, Calif., reported the settlement of all ongoing litigation between the two companies, including patent, antitrust, unfair business practice and other business tort claims. The agreement provides Koru with freedom to operate under Emed’s existing patent portfolio, dismissal of all litigation with prejudice, and an equity payment to Emed.

Columbia, S.C.-based Seti Electronics Corp. Technology Inc. said it will release portable air purifiers with Violeds technology for COVID-19 disinfection in early June.

Siemens Healthineers, based in Erlangen, Germany, has begun shipping its total antibody test and molecular test kit for COVID-19 in the U.S. The company already has FDA emergency use authorization for the PCR molecular SARS-CoV-2 detection test kit and is pursuing an FDA EUA for its CE-marked antibody test. Roughly 20,000 systems have been deployed worldwide, with plans to ramp up capacity to more than 50 million antibody tests per month as the pandemic continues.

Skywater Technology Inc., of Bloomington, Minn., has been chosen by New York-based Asymmetric Return Capital LLC and Linear Asics Inc., of Tallmadge, Ohio, to volume manufacture a temperature-sensing microchip for a low-cost, smartphone-enabled, wireless patch to assist in the remote detection of COVID-19.

St Robotics, of Princeton, N.J., and Cambridge, U.K., said it is ramping up shipments of four-, five- and six-axis industrial robots to meet heightened demand from COVID-19. Mesa Laboratories Inc., in Bozeman, Mont., is using the robotic systems to increase production and flexibility for the vapor hydrogen peroxide sterilization of its Apex biological indicator products.

Velano Vascular Inc., of San Francisco, has made its new streamlined remote training tool available to U.S. hospitals to aid in the COVID-19 response. The platform was developed to enable broader use of Velano’s Pivo needle-free blood draw device.

Irving, Texas-based Vizient Inc. is partnering with IBM Watson Health, of Cambridge, Mass., to support health care providers performance improvement needs. Under the agreement, IBM Watson Health is withdrawing its Actionoi, Carediscovery and Market Expert offerings from its portfolio and providing clients a path to transition to Vizient’s Operational Data Base, Clinical Data Base and Sg2 Market Edge products.

No Comments